Perseus Proteomics Inc. (4882) said on Nov. 20 it will issue 46,000 moving-strike warrants, its 31st series, to Macquarie Bank Limited via third-party allotment, covering 4.6 million potential shares and raising ¥470.5 million based on the initial exercise price of ¥102.
The warrants are priced at ¥29 each, or ¥1,334,000 in total, and each converts into 100 shares. Exercising all of them at the initial price would bring in ¥469.2 million, for estimated net proceeds of ¥459.5 million.
From the second exercise onward, the exercise price resets to 92% of the previous trading day's close on the Tokyo Stock Exchange, with no upper limit and a floor of ¥56. The share count remains 4.6 million even at the floor. For exercises classified as exceeding exchange limits, the price cannot fall below the Nov. 20, 2026 close. Proceeds will change if the price is revised or warrants go unexercised.
Founded in February 2001, the antibody drug developer posted an operating loss of ¥744 million and operating cash outflow of ¥653 million for the year ended March 2026. It held ¥1.42 billion in cash and deposits at end-September 2026 and booked an operating loss of ¥412 million for the first half of the fiscal year ending March 2027. The ¥705 million raised through its 29th warrants, issued Jan. 5, 2026, is expected to be fully spent on R&D and operations by end-June 2027.
The company said its antibody-drug conjugate PPMX-T004, developed with UBE Corp., completed preliminary toxicity studies at end-September 2026, and that GLP toxicity studies will require GMP investigational drug manufacturing preparation. It does not currently expect licensing revenue from PPMX-T002 and PPMX-T003.
Next steps: The allotment date is Dec. 8, 2026, and the exercise period runs Dec. 9, 2026-Dec. 8, 2028. The purchase agreement will be signed after the securities registration takes effect.
| I-ne | |
| Tender offer price | ¥2,248 per share |
| Kadoya Seiyu | |
| Tender offer price | ¥2,655 per share |
| TKP Corporation | |
| Effective date | March 1, 2027 (scheduled) |
| M3, Inc. | |
| Tender offer price | ¥1,619 per share |
| Digital Hearts Holdings | |
| Consolidation ratio | 2,975,211 shares into 1 share |
| Shoei Corporation | |
| Shares transferred | 1.8 million shares |
| TOSE Co., Ltd. | |
| Effective date (scheduled) | Jan. 4, 2027 |
| NSK Ltd. | |
| Share transfer ratio (NSK:NTN) | 1:0.353 |
| M&A / TOB | 20 |
| Guidance | 7 |
| Buybacks | 11 |
| Dividends | 4 |
| Capital | 12 |
| Earnings | 16 |
| People | 3 |
Summaries of public disclosures by Japanese listed companies. Not investment advice; accuracy not guaranteed. Figures and dates in the TDnet originals prevail.
本站內容為日本上市公司公開開示之摘要整理,非投資建議,亦不保證正確。數字與日程以 TDnet 原文為準。
本サイトは日本の上場企業の適時開示を要約したものであり、投資助言ではありません。正確性は保証しません。数値・日程は TDnet の原文が優先します。